Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

This study has been terminated.
(The Principal Investigator left the clinic and there was no one who could take over this study.)
Information provided by:
Novartis Identifier:
First received: August 23, 2005
Last updated: December 14, 2007
Last verified: December 2007
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2004
  Estimated Primary Completion Date: No date given